HC Wainwright Cuts Vera Therapeutics (NASDAQ:VERA) Price Target to $90.00

15 Aug 2026, 06:36 by Mitch Edgeman · The Markets Daily

Vera Therapeutics (NASDAQ:VERA – Free Report) had its price target decreased by HC Wainwright from $125.00 to $90.00 in a research note released on Wednesday, Marketbeat.com reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Vera Therapeutics’ Q3 2026 earnings at ($1.64) EPS, Q4 2026 earnings at ($1.66) EPS, FY2026 earnings at ($6.52) EPS, Q1 2027 earnings at ($1.51) EPS, Q2 2027 earnings at ($1.35) EPS, Q3 2027 earnings at ($0.98) EPS, Q4 2027 earnings at ($0.54) EPS, FY2027 earnings at ($4.38) EPS, FY2028 earnings at $0.49 EPS, FY2029 earnings at $5.21 EPS and FY2030 earnings at $8.79 EPS.

Several other research analysts also recently weighed in on the company. Needham & Company LLC set a $125.00 target price on Vera Therapeutics in a research note on Wednesday, July 8th. Raymond James Financial restated a “strong-buy” rating and set a $84.00 price objective on shares of Vera Therapeutics in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a report on Friday, July 17th. Bank of America lifted their target price on shares of Vera Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Finally, William Blair reissued an “outperform” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Vera Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $81.15.

Read Our Latest Stock Report on VERA

Vera Therapeutics Trading Up 9.5%

Shares of Vera Therapeutics stock opened at $31.63 on Wednesday. The firm has a 50-day simple moving average of $36.38 and a two-hundred day simple moving average of $38.51. The company has a debt-to-equity ratio of 0.18, a quick ratio of 13.64 and a current ratio of 10.92. Vera Therapeutics has a fifty-two week low of $21.15 and a fifty-two week high of $56.05. The company has a market cap of $2.27 billion, a P/E ratio of -5.40 and a beta of 0.92.

Vera Therapeutics (NASDAQ:VERA – Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($1.52) EPS for the quarter, beating analysts’ consensus estimates of ($1.58) by $0.06. During the same period last year, the firm earned ($1.20) EPS. As a group, equities analysts predict that Vera Therapeutics will post -6.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Vera Therapeutics news, CEO Marshall Fordyce sold 46,250 shares of the firm’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total value of $1,956,375.00. Following the transaction, the chief executive officer owned 151,994 shares in the company, valued at approximately $6,429,346.20. This trade represents a 23.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 15.90% of the company’s stock.

Institutional Investors Weigh In On Vera Therapeutics

A number of hedge funds have recently modified their holdings of the business. Price T Rowe Associates Inc. MD lifted its stake in shares of Vera Therapeutics by 49.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company’s stock worth $276,595,000 after buying an additional 1,795,537 shares in the last quarter. Deerfield Management Company L.P. grew its stake in Vera Therapeutics by 8.8% during the 3rd quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company’s stock valued at $105,812,000 after acquiring an additional 293,040 shares in the last quarter. Vanguard Group Inc. grew its stake in Vera Therapeutics by 11.9% during the 4th quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock valued at $180,805,000 after acquiring an additional 379,748 shares in the last quarter. Vestal Point Capital LP raised its holdings in Vera Therapeutics by 24.0% in the 2nd quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock valued at $73,036,000 after acquiring an additional 600,000 shares during the last quarter. Finally, Eversept Partners LP raised its holdings in Vera Therapeutics by 9.4% in the 4th quarter. Eversept Partners LP now owns 3,072,304 shares of the company’s stock valued at $155,581,000 after acquiring an additional 264,468 shares during the last quarter. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Vera Therapeutics

Here are the key news stories impacting Vera Therapeutics this week:

Positive Sentiment: HC Wainwright maintained a Buy rating and $90 price target, substantially above Vera’s recent trading level. The firm modestly improved its FY2026 EPS forecast to a loss of $6.52 from $6.79 and raised its Q3 and Q4 2026 estimates to losses of $1.64 and $1.66, respectively. HC Wainwright Lowers Vera Therapeutics Price Target to $90
Positive Sentiment: HC Wainwright continues to project a path toward profitability, forecasting positive EPS of $0.49 in FY2028, $5.21 in FY2029 and $8.79 in FY2030. The firm also expects quarterly losses to narrow through 2027, which supports the longer-term investment case.
Neutral Sentiment: Near-term estimates remain broadly consistent with continued losses: HC Wainwright forecasts FY2027 EPS of negative $4.38, compared with the current consensus estimate of negative $6.45 for the current year. Investors are likely focused on Vera’s ability to fund operations and advance its pipeline until commercial revenue develops.
Negative Sentiment: HC Wainwright materially reduced its longer-term profitability forecasts, cutting FY2027 EPS from negative $3.84 to negative $4.38, FY2028 from $2.20 to $0.49, FY2029 from $9.11 to $5.21 and FY2030 from $10.83 to $8.79. These reductions imply a slower earnings ramp and may limit enthusiasm despite the Buy rating.
Negative Sentiment: A separate Wedbush note was characterized as a pessimistic forecast for VERA, adding a more cautious counterpoint to HC Wainwright’s bullish rating. Wedbush Issues Pessimistic Forecast for Vera Therapeutics

About Vera Therapeutics

(Get Free Report)

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.